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INTRODUCTION
Behcet’s Disease (BD; MIM 109650) is a chronic multi-
system inflammatory disorder of unclear etiology, which is
characterized by primary features including recurrent oral and
genital ulcers as well as skin and ocular lesions. Other minor
manifestations of BD include arthritis, large vessel involve-
ment (LVI), and lesions of central nervous system (CNS) and
gastrointestinal (GI) tract. The mean age of onset of BD is
in the early 30s, and the male-to-female ratio varies with eth-
nicity (1). Although the precise pathogenesis of BD remains
a matter of some controversy, genetic, immunological, and
environmental factors have been suggested to contribute to
the development of BD (2). Several susceptibility variant gene-
tic alleles, including alleles of Th1 cytokine-associated genes,
have been recognized for their effects on the clinical symp-
toms of BD. A recent study of Turkish multicase families
identified several BD susceptibility loci, via whole-genome
linkage analysis. The loci with the strongest association with
BD were detected at positions 6p22-24 and 12p12-13 (3).
Tumor necrosis factor alpha (TNF- ) is a multifunctional,
pro-inflammatory cytokine, which performs a variety of func-
tions in innate immune response, including activation of mac-
rophages and apoptosis, which appears to be responsible for
the recurrent inflammatory reactions encountered in BD pa-
tients. The promoter polymorphism of the TNFA gene, which
is located on chromosome 6p21.3, has been associated with
the expression of TNF- . TNF- levels tend to be signifi-
cantly elevated in active BD patients, and increased production
of TNF- have been associated with clinical deterioration (4,
5). Several single nucleotide polymorphisms (SNPs) in the
TNFA promoter region appear to alter transcription efficiency
in response to specific external stimuli (6-8). Excessive or insuf-
ficient TNF- production might be responsible for the vari-
able patterns of the pathogenesis of this disease. These SNPs,
as well as TNF- overproduction, have been associated with
susceptibility to or with the severity of, both inflammatory
diseases and autoimmune diseases, including rheumatoid ar-
thritis, systemic lupus erythematosus, and Crohn’s disease (9).
There is, currently, a large body of evidence from in vitro exper-
iments which suggests that TNF- is produced at higher
levels in both the monocytes and  / T cells of BD patients
in response to lipopolysaccharide treatment than has been
observed in control subjects. However, the mechanism under-
lying this phenomenon remains to be determined (10, 11).
Also, infliximab (monoclonal anti-TNF- antibody) and etan-
ercept (a dimeric soluble p75 TNF receptor) have demonstrat-
ed a high degree of therapeutic efficacy for suffers of BD cou-
pled with uveitis, intestinal ulcers, and orogenital ulcers (12,
13).
Researchers have been attempting for several years to deter-
mine whether polymorphisms of the TNFA promoter region
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Association of TNFA Promoter Region Haplotype in Behcet’ s Disease
Although the etiology of Behcet’s Disease (BD; MIM 109650) remains to be clearly
elucidated, levels of tumor necrosis factor alpha (TNF- ) have been reported to be
significantly elevated in BD patients, and TNF- blockers have been demonstrated
to exhibit some degree of therapeutic efficacy for a certain subset of BD sufferers.
In this study, we have conducted an analysis of the TNFA haplotypes in the promoter
response element that affect the binding affinity of specific transcription factors, in
order to characterize their association with the clinical features of BD. Six polymor-
phisms in the promoter region of TNFA were genotyped in 254 BD patients and 344
control subjects, via the PCR-RFLP technique. TNFA -1031*C, -863*A and -308*G
alleles were associated with an increased risk of BD (p=0.030, OR=1.4; p=0.008,
OR=1.5; p=0.010, OR=1.8, respectively). The sole TNFA haplotype -1031C-863A-
857C-376G-308G-238G, was associated with a 1.6 fold increase in the risk of BD,
whereas the TNFA haplotype -1031T-863C-857C-376G-308A-238G was associat-
ed with a 0.6 decreased risk of BD. The TNFA -1031*C, -863*A, -857*C and -308*G
alleles were significantly associated with BD. The findings of this study, collectively,
indicate that TNFA haplotypes in the promoter response elements may exert sig-
nificant influence on susceptibility to BD.
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influence the expression of TNF- in BD or its susceptibility
or its severity and clinical features. The results of these allelic
and genotypic associations, however, are somewhat contra-
dictory, as the implicated polymorphic sites and allele fre-
quencies appear to vary substantially among ethnic groups
(14, 15). Most notably, -376G>A and -308G>A are either
completely absent or quite rare among Asians, including the
Koreans and the Japanese (6, 16, 17). Therefore, this study
was focused specifically on the haplotypic association of TNFA
promoter response elements with the risks and clinical fea-
tures of BD.
MATERIALS AND METHODS
Subjects
Two hundred fifty-four patients (130 males and 124 females)
from 16 to 66 yr of age registered at the Behcet’s Disease Spe-
cialty Clinic of Severance Hospital at the Yonsei University
College of Medicine and the Ajou University School of Medi-
cine and 344 healthy Korean controls were included in this
case-control study. The youngest onset of BD was 3 yr old
and the oldest onset was 58 yr old and the mean age of dis-
ease onset was 33.2±10.4 yr old. BD was diagnosed accor-
ding to the clinical criteria of the International Study Group
for Behcet’s Disease or the revised criteria of Behcet’s Disease
(18). 
Genotyping of TNFA
Genomic DNA was extracted from peripheral blood by
using a QIAamp Blood Mini kit (Quiagen, Valencia, CA,
U.S.A.). Six SNPs in the promoter region of TNFA gene at
the position of -1031 T>C,-863 C>A,-857 C>T,-376 G>A,
-308 G>A and -238 G>A (according to GenBank accession
No. AB088112) were analyzed by using polymerase chain
reaction (PCR) and restriction fragment length polymorphism
(RFLP) methods. The -1031 T>C was amplified with PCR
by using primers 5′ -ACAAGGCTGACCAAGAGAGAA-3′
and 5′ -GTCCCCATACTCGACTTTCAT-3′ and was digest-
ed with the BbsI restriction enzyme (19). The -863 C>A was
amplified by using primers 5′ -GGCTCTGAGGAATGGGT-
TAC-3′ and 5′ -CTACATGGCCCTGTCTTCGTTACG-3′
and was digested with the TaiI restriction enzyme (20). The
reverse primer contained one mismatched nucleotide sequence
(underlined). Genotyping for -857C>T was conducted by
using the forward primer 5′ -AAGTCGAGTATGGGGAC-
CCCCCGTTAA-3′ and the reverse primer 5′ -CCCCAGT-
GTGTGGCCATATCTTCTT-3′ which made it possible to
use the restriction enzyme HincII (19). The G>A substitution
at position -376 was analyzed by the Tsp509I restriction en-
zyme by using the primers, 5′ -CCCCGTTTTCTCTCCCT-
CAA-3′ and 5′ -TGTGGTCTGTTTCCTTCTAA-3′ (21). The
polymorphic region containing the NcoI restriction site at -308
G>A was amplified by using primers 5′ -AGGCAATAGG-
TTTTGAGGGCCAT-3′ and 5′ -TCCTCCCTGCTCCGA-
TTCCG-3′ . The G>A transition polymorphism at position
-238 was examined by PCR using primers 5′ -CCCAGAAG-
ACCCCCCTCGGAACC-3′ and 5′ -ACCTTCTGTCTCGG-
TTTCTTCTCCATCGC-3′ and was digested with the HpaII
restriction enzyme (19). The digested PCR products were
electrophoresis on an 8% or 5% polyacrylamide gel and were
stained with ethidium bromide to visualize the DNA frag-
ments.
Statistical analysis
The Hardy-Weinberg equilibrium and Linkage disequili-
brium coefficient Lewontin’s D′ ( │ D′ │ ) were performed with
the R program v.1.9.1 (http://cran.r-project.org). The statis-
tical significance of the difference in TNFA allele frequencies
between BD patients and controls was examined by the  2
or Fisher’s exact test by using SAS version 8.1 (SAS Institute,
Cary, NC, U.S.A.). Haplotypes of each individual were inferred
by using the PHASE program, v.2.0.1 (22). A p-value of less
than 0.05 was considered statistically significant.
RESULTS
A total of 254 Korean BD patients and 344 control subjects
were analyzed for six SNPs in the TNFA promoter region.
The genotype and allele frequencies of the regulatory res-
ponse element promoter polymorphisms TNFA gene of the
BD patients and controls are shown in Table 1. Distributions
of the genotypes of both groups agree with those predicted
under the conditions of Hardy-Weinberg equilibrium. The
TNFA -376G>A was not polymorphic in the Korean pop-
ulation. The TNFA -1031*C, -863*A and -308*G alleles
are shown to be significantly associated with BD (p=0.030,
odds ratio [OR]=1.4; p=0.008, OR=1.5; p=0.010, OR=1.8,
respectively). They were significantly higher in the BD patients
suffering from major symptoms (OR=1.4-1.9) and arthritis
(OR=1.4-2.9) than in the controls (Table 2). There was no
association between the presence of minor -238*A allele and
the symptoms of BD except for BD with GI lesions.
The age at which an individual first manifests major symp-
toms of the BD appears to be genetically influenced. The
TNFA promoter SNPs influenced the age onset (before 20
yr) in BD. The TNFA -1031*C, -863*A and -857*C alleles
were shown to have a significantly higher association among
the BD patients whose onset age is younger than 20 yr old
when compared with those whose onset age is after 20 yr old
(p=0.03-0.04, OR=1.6-2.5). Significant differences between
BD and controls were observed in the distribution of TNFA
-1031*C, -863*A and -857*C did show significantly higher
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(OR=1.6-2.5) (Fig. 1).
TNFA promoter polymorphisms showed linkage disequi-
librium in the Korean population (Table 3). The TNFA-
1031*T was strong associated with -863*C (p<0.0001) and
-857*C (p<0.0001). The -863*C was in linkage disequilibri-
um with the -857*C (p=0.0003). Among 22 estimated hap-
lotypes, the most common haplotype, TNFA -1031T-863C
-857C-376G-308G-238G (55%) and six common TNFA
haplotypes were observed in the Korean population. The over-
all haplotype distributions were found to be significantly dif-
ferent between the BD patients and the controls by the per-
mutation test (p=0.02). The TNFA -1031C-863A-857C-
376G-308G-238G haplotype containing the three alleles
TNFA -1031*C, -863*A and -308*G was found to be sig-
nificantly associated with BD. Conversely, the TNFA -1031T
-863C-857C-376G-308A-238G which did not have these
alleleic polymorphisms was protective against BD (Table 4).
The patients were characterized by clinical features whose
Polymorphisms BD
n=254 (%)
Controls
n=344 (%)
p
OR 
(95% CI)
-1031T>C (rs1799964)
-1031*T/*T 145 (57.1) 222 (64.5)
-1031*T/*C 94 (37.0) 112 (32.5)
-1031*C/*C 15 (5.9) 10 (2.9)
-1031*C 0.244 0.192 0.030 1.4 (1.03-1.80)
-863C>A (rs1800630)
-863*C/*C 163 (64.2) 251 (73.0) 0.021 0.7 (0.47-0.94)
-863*C/*A 80 (31.5) 88 (25.6)
-863*A/*A 11 (4.3) 5 (1.4) 0.031 3.1 (1.05-8.95)
-863*A 0.201 0.142 0.008 1.5 (1.12-2.05)
-857C>T (rs1799724)
-857*C/*C 190 (74.8) 243 (70.6)
-857*C/*T 61 (24.0) 90 (26.2)
-857*T/*T 3 (1.2) 11 (3.2)
-857*C 0.868 0.837
-376G>A (rs1800750)
-376*G/*G 254 (100.0) 344 (100.0)
-376*G/*A 0 (0.0) 0 (0.0)
-376*A/*A 0 (0.0) 0 (0.0)
-376*A 00
-308G>A (rs1800629)
-308*G/*G 227 (89.4) 283 (82.3) 0.015 1.8 (1.12-2.94)
-308*G/*A 27 (10.6) 58 (16.9)
-308*A/*A 0 (0.0) 3 (0.8)
-308*G 0.947 0.907 0.010 1.8 (1.15-2.91)
-238G>A (rs361525)
-238*G/*G 233 (91.7) 325 (94.5)
-238*G/*A 21 (8.3) 18 (5.2)
-238*A/*A 0 (0.0) 1 (0.3)
-238*A 0.041 0.029
Table 1. Genotype and allele frequencies of the TNFA promoter
SNPs in BD patients and controls
No. p
OR 
(95% CI)
p
OR 
(95% CI)
p
OR 
(95% CI)
p
OR 
(95% CI)
p
OR 
(95% CI)
-1031*C -863*A -857*C -308*G -238*A
Controls 344 0.192 0.142 0.837 0.907 0.029
BD  total 254 0.244 0.030 1.4 0.201 0.008 1.5 0.868 0.139 1.3 0.947 0.010 1.8 0.041
(1.03-1.80) (1.12-2.05) (0.92-1.78) (1.15-2.91)
Oral  ulcers 254 0.244 0.030 1.4 0.201 0.008 1.5 0.868 0.139 1.3 0.947 0.010 1.8 0.041
(1.03-1.80) (1.12-2.05) (0.92-1.78) (1.15-2.91)
Skin  lesions 230 0.254 0.012 1.4 0.209 0.003 1.6 0.878 0.054 1.4 0.950 0.007 1.9 0.043
(1.08-1.91) (1.16-2.17) (0.99-1.98) (1.19-3.19)
Genital  ulcers 205 0.261 0.073 1.5 0.212 0.003 1.6 0.876 0.083 1.4 0.949 0.012 1.9 0.041
(1.11-1.99) (1.18-2.23) (0.96-1.95) (1.14-3.16)
Ocular  lesions 182 0.255 0.017 1.4 0.212 0.004 1.6 0.868 0.184 1.3 0.948 0.020 1.9 0.038
(1.07-1.96) (1.16-2.25) (0.89-1.84) (1.10-3.16)
Arthritis 118 0.256 0.042 1.4 0.220 0.005 1.7 0.877 0.141 1.4 0.966 0.004 2.9 0.034
(1.01-2.04) (1.17-2.48) (0.90-2.15) (1.38-6.19)
Large vessel 46 0.250 0.217 0.880 0.902 0.033
involvement
Central  nervous 15 0.400 0.053 2.8 0.300 0.016 2.6 0.967 0.031 5.6 0.967 0.067
system lesions (1.32-5.97) (1.15-5.80) (0.76-41.82)
Gastro intesti- 14 0.321 0.143 0.821 0.964 0.107 0.046 4.0 
nal lesions (1.12-14.38)
Table 2. The allele frequency of TNFA for clinical feature of BD patients
-238*A
-308*G
-857*C
-863*A
-1031*C
0.03
0.14
0.19
0.84
0.91
Frequency
p=0.039, OR=1.7
p=0.007, OR=2.0
Controls
Onset age more than 20 yr
p=0.033, OR=2.5
p=0.010, OR=2.9
p=0.051, OR=1.4 p=0.0005, OR=2.4
p=0.046, OR=1.6
p=0.003, OR=2.0
Fig. 1. Allele frequency of the TNFA promoter in BD onset age.
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major/minor symptoms were oral, genital ulcers, skin, ocular
lesions, arthritis, and LVI. The CNS and GI lesions are rare.
We investigated the clinical features of the TNFA haplotype-
positive individuals in terms of the frequency of the haplotype,
TNFA -1031C-863A-857C-376G-308G-238G, which con-
tains the three alleles -1031*C, -863*A and -308*G. Being
compared with the controls, it was significantly over-repre-
sented among patients (OR=1.6-3.0) who suffered from oral
and genital ulcers, skin and ocular lesions, arthritis and CNS
but not among those who suffered from LVI or GI lesions.
On the other hand, the haplotype TNFA -1031T-863C-857C-
376G-308A-238G which does not carry those alleles were
shown to significantly reduce the risk of BD than in controls
(p=0.029-0.013, OR=0.4-0.6) (Table 4). Frequencies of TNFA
-1031T-863C-857T-376G-308G-238G and TNFA -1031C-
863C-857C-376G-308G-238A haplotypes in the patients
with CNS or GI lesions significantly differed from those in
the controls, but the number of patients was too small for a
statistical analysis (Table 4).
DISCUSSION
Both clinical and polymorphism-focused studies have un-
covered evidence suggesting that TNF- functions as a media-
tor in the initiation and propagation of BD. Polymorphisms
of the TNFA promoter region have been associated with BD
in several ethnic groups, but it remains somewhat uncertain
as to whether this is the results of the existence of suscepti-
bility sites, or to the level of TNF- expression. In this study,
a significant difference was observed between BD patients
and controls with regard to the polymorphisms of the regu-
latory response promoter region of the TNFA gene. The alle-
les, TNFA -1031*C, -863*A and -308*G were closely asso-
ciated with BD, but TNFA -376G>A and -238G>A were
not significantly associated among Korean sufferers of BD.
These results are consistent with findings of studies employing
different ethnic groups. The TNFA -1031*C allele was stro-
ngly association with BD in Caucasian patients, in a previous
study conducted in the United Kingdom (23). The other
previous studies involving Turkish and Caucasian patients,
the TNFA -376G>A, -308G>A and -238G>A alleles were
not significantly associated with BD (15, 23-25). In studies
of haplotypes of the TNFA promoter, the TNFA -1031C-
863A-857C-376G-308G-238G haplotype, which harbors
│ D ′ │value is given above the diagonal; p value is given below the diag-
onal.
│ D ′ │
-1031T>C -863C>A -857C>T -308G>A -238G>A
p -1031T>C - 0.850 0.998 0.655 0.772
-863C>A <0.0001 - 0.772 0.524 0.988
-857C>T <0.0001 0.0003 - 0.996 0.605
-308G>A 0.007 0.073 0.0002 - 0.447
-238G>A <0.0001 0.068 0.226 0.516 -
Table 3. Linkage disequilibria ( │ D′ │ ) among SNP of TNFA in the
Korean population (n=344)
Haplotype
Controls
(n=688)
BD
(n=508)
Oral ulcers
(n=508)
Skin 
lesions
(n=460)
Genital 
ulcers
(n=410)
Ocular lesions
(n=364)
Arthritis
(n=236)
Large
vessel
involve-
ment
(n=92)
Central ner-
vous system
lesions
(n=30)
Gastro-
intestinal
lesions
(n=28)
-1031T>C-863C>A-857C>T-376G>A-308G>A-238G>A
T-C-C-G-G-G 0.549 0.557 0.557 0.558 0.550 0.554 0.565 0.516 0.530 0.469
T-C-T-G-G-G 0.151 0.128 0.128 0.118 0.120 0.126 0.119 0.102 0.033 0.172
p=0.042
0.2 (0.03-1.44)
C-A-C-G-G-G 0.123 0.185 0.185 0.190 0.196 0.191 0.198 0.190 0.284 0.142
p value p=0.003 p=0.003 p=0.002 p=0.001 p=0.003 p=0.004 p=0.008
OR 1.6  1.6  1.7  1.7  1.7  1.8  3.0 
(95% CI) (1.17-2.22) (1.17-2.22) (1.19-2.29) (1.23-2.40) (1.20-2.39) (1.19-2.61) (1.35-6.86)
T-C-C-G-A-G 0.082 0.050 0.050 0.047 0.048 0.044 0.032 0.089 0.019 0.029
p=0.029 p=0.029 p=0.027 p=0.039 p=0.022 p=0.013
0.6   0.6  0.6  0.6  0.5  0.4 
(0.36-0.95) (0.36-0.95) (0.34-0.94) (0.34-0.98) (0.29-0.92) (0.19-0.84)
C-C-C-G-G-G 0.038 0.024 0.024 0.027 0.030 0.025 0.031 0.042 0.043 0.074
C-C-C-G-G-A 0.023 0.031 0.031 0.032 0.030 0.029 0.026 0.005 0.053 0.105
p=0.029
5.0 
(1.38-18.42)
T-A-C-G-G-G 0.011 0.010 0.010 0.011 0.010 0.011 0.017 0.009 0.010 0.000
Others 0.023 0.015 0.015 0.017 0.016 0.020 0.012 0.047 0.028 0.009
Table 4. Clinical features associated with TNFA haplotype600 K.S. Park, N.Y. Kim, J.H. Nam, et al.
the -1031*C, -863*A and -308*G alleles, was significantly
associated with BD. Conversely, the TNFA -1031T-863C-
857C-376G-308A-238G haplotype, which does not harbor
the aforementioned allelic polymorphisms, was associated with
a reduced susceptibility to BD. The same results were report-
ed in Caucasian BD patients in the United Kingdom (23). We
compared the risk of BD between the early onset age group
and the later onset of group, with regard to the TNFA alleles.
The -1031*C, -863*Aand -857*Calleles were detected with
a significantly greater frequency in the former than in the
latter.
Inflammation in cases of BD is believed to be mediated by
cytokines derived from T-helper type 1 lymphocytes, includ-
ing TNF- (26). It appears that disease activity can be signifi-
cantly associated with the secretion of pro-inflammatory me-
diators, as the result of the direct activation of circulating
monocytes. The pro-inflammatory cytokine, TNF- , trig-
gers a signaling cascade, converging on the activation of the
NF- B transcription factor, which is also involved in a vari-
ety of features of immune response, which in turn constitutes
the basis for a host of physiological and pathological processes.
The TNF- /NF- B pathway also appears to be relevant to
human diseases (27). The enhanced/silenced expression of
pro-inflammatory cytokines indicates the presence of a defect
in the normal regulatory mechanisms, and this may have a
genetic basis. Much of the control of gene expression appears
to involve transcription factors (trans-acting) bound to prox-
imal promoter regulatory response sequences (cis-acting). Gene
expression is mediated by several sets of cis-acting regulato-
ry regions, including the core or proximal promoter region,
and the response elements. The response elements modulate
transcription in response to specific external stimuli, includ-
ing heat shock 70 or interferon-gamma. The response ele-
ments are normally located a short distance upstream of the
promoter elements. Allele-specific elements may bind the
transcriptional factors, OCT-1 and NF- B, in the -1031T>
C, -863C>A and -857C>T of the TNFA regulatory response
promoter region, which are thought to be involved in a vari-
ety of the immune response functions. Although the roles of
the allele-dependent binding elements of TNFA -1031, -863
and -857 SNPs have yet to be precisely delineated, the sus-
ceptible sites associated with the development of BD are in
the -1031T>C, -863C>A and -857C>T SNPs of the regula-
tory response promoter region, and not in -376G>A, -308G>
A or -238G>A (6, 15, 28-30). These SNPs also evidenced
no relationship with the degree of severity of the clinical fea-
tures of BD (15).
The pro-inflammatory cytokines, TNF- and mannose-
binding lectin (MBL), are potent inducers of inflammation.
Elevated levels of these cytokines are frequently associated
with the activation of macrophages, thereby influencing the
severity of inflammatory responses. Both of these pro-inflam-
matory cytokines induce local inflammatory responses, and
also exert systemic effects. The over-expression of these cyto-
kines may be responsible for the pathogenesis of recurrent
BD. It has been reported previously that the MBL2 HYPA
haplotype, which induces an elevate expression of MBL, was
related to susceptibility to BD, and also to the early onset of
disease (31, 32). TNF- production tended to be elevated in
carriers of the TNFA -1031*C, -863*A or -857*T alleles,
who also suffered from severe periodontitis (19). The frequen-
cy with which individuals were determined to harbor both
the TNFA -1031C-863A-857C-376G-308G and MBL2
HY-- (-550*G, -221*G) haplotypes was significantly higher
in the BD patient group than among the controls (p=0.004).
The elevated production of TNF- and MBL2 haplotypes
might serve to accelerate recurrent inflammation, or may play
a critical pathogenic role in initiating immune responses,
which might also result in the development of BD. A host
of genes appear to be related to BD susceptibility, and the
TNFA promoter haplotypes appear to be fairly important
markers with regard to their association with BD.
In conclusion, the findings of this study indicate that the
TNFA -1031C-863A-857C-308G haplotype can be confi-
dently associated with the development of BD as well as early
age of onset. This haplotype was also determined to be respon-
sible for the enhanced inflammatory reactions seen in cases
of BD involving primary symptoms. 
REFERENCES
1. Bang DS, Oh SH, Lee KH, Lee ES, Lee SN. Influence of sex on pa-
tients with Behcet’s disease in Korea. J Korean Med Sci 2003; 18:
231-5.
2. Zierhut M, Mizuki N, Ohno S, Inoko H, Gul A, Onoe K, Isogai E.
Immunology and functional genomics of Behcet’s disease. Cell Mol
Life Sci 2003; 60: 1903-22.
3. Karasneh J, Gul A, Ollier WE, Silman AJ, Worthington J. Whole-
genome screening for susceptibility genes in multicase families with
Behcet’s disease. Arthritis Rheum 2005; 52: 1836-42.
4. Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B. Serum inter-
leukin 18 and tumor necrosis factor-alpha levels are increased in
Behcet’s disease. Clin Exp Dermatol 2005; 30: 61-3.
5. Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroglu IC, Dundar S,
Kirazli S. Cytokines in Behcet’s disease. J Rheumatol 1996; 23: 321-2.
6. Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh
K. Polymorphism of the 5′ -flanking region of the human tumor necro-
sis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998; 51:
605-12.
7. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW.
Effects of a polymorphism in the human tumor necrosis factor alpha
promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;
94: 3195-9.
8. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis
factor-alpha promoter polymorphism effects transcription. Mol Im-
munol 1997; 34: 391-9.
9. Negoro K, Kinouchi Y, Hiwatashi N, Takahashi S, Takagi S, Satoh J,TNFA Haplotype in Behcet’s Disease 601
Shimosegawa T, Toyota T. Crohn’s disease is associated with novel
polymorphisms in the 5′ -flanking region of the tumor necrosis factor
gene. Gastroenterology 1999; 117: 1062-8.
10. Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H,
Ocal L, Inanc M, Capo C. Overproduction of monocyte derived tumor
necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil
superoxide generation in Behcet’s disease. A comparative study with
familial Mediterranean fever and healthy subjects. J Rheumatol 1993;
20: 1544-9.
11. Yamashita N, Kaneoka H, Kaneko S, Takeno M, Oneda K, Koizumi
H, Kogure M, Inaba G, Sakane T. Role of  / T lymphocytes in the
development of Behcet’s disease. Clin Exp Immunol 1997; 107: 241-7.
12. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Marko-
michelakis NN. Effect of infliximab on sight-threatening panuveitis
in Behcet’s disease. Lancet 2001; 358: 295-6.
13. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S,
Hamuryudan V, Yazici H. Short-term trial of etanercept in Behcet’s
disease: a double blind, placebo controlled study. J Rheumatol 2005;
32: 98-105.
14. Allen RD. Polymorphism of the human TNF-alpha promoter; random
variation or functional diversity? Mol Immunol 1999; 36: 1017-27.
15. Ates AK, Kinikli G, Duzgun N, Duman M. Lack of association of
tumor necrosis factor-alpha gene polymorphisms with disease sus-
ceptibility and severity in Behcet’s disease. Rheumatol Int 2006; 26:
348-53. 
16. Wang XT, Ohtsuka Y, Kimura K, Muroi M, Ishida T, Saito J, Muna-
kata M. Antithetical effect of tumor necrosis factor-alpha gene poly-
morphism on coal workers’ pneumoconiosis (CWP). Am J Ind Med
2005; 48: 24-9.
17. Lee EB, Kim JY, Lee YJ, Park MH, Song YW. TNF and TNF recep-
tor polymorphisms in Korean Behcet’s disease patients. Hum Immunol
2003; 64: 614-20.
18. International Study Group for Behcet’s Disease. Criteria for diagno-
sis of Behcet’s disease. Lancet 1990; 335: 1078-80.
19. Soga Y, Nishimura F, Ohyama H, Maeda H, Takashiba S, Murayama
Y. Tumor necrosis factor-alpha gene (TNF-alpha) -1031/-863, -857
single-nucleotide polymorphisms (SNPs) are associated with severe
adult periodontitis in Japanese. J Clin Periodontol 2002; 30: 524-31.
20. Skoog T, van’t Hooft FM, Kallin B, Jovinge S, Boquist S, Nilsson J,
Eriksson P, Hamsten A. A common functional polymorphism (C->A
substitution at position -863) in the promoter region of the tumour
necrosis factor-alpha (TNF-alpha) gene associated with reduced cir-
culating levels of TNF-alpha. Hum Mol Genet 1999; 8: 1443-9.
21. Moukoko CE, El Wali N, Saeed OK, Mohamed-Ali Q, Gaudart J,
Dessein AJ, Chevillard C. No evidence for a major effect of tumor
necrosis factor alpha gene polymorphisms in periportal fibrosis caused
by Schistosoma mansoni infection. Infect Immun 2003; 71: 5456-60.
22. Stephens M, Smith NJ, Donnelly P. A new statistical method for
haplotype reconstruction from population data. Am J Hum Genet
2001; 68: 978-89.
23. Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-
Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford
MR, Welsh KI, Marshall SE, Jewell DP. Mapping the HLA associ-
ation in Behcet's disease: a role for tumor necrosis factor polymor-
phisms? Arthritis Rheum 2003; 48: 807-13.
24. Duymaz-Tozkir J, Gul A, Uyar FA, Ozbek U, Saruhan-Direskeneli
G. Tumour necrosis factor-alpha gene promoter region -308 and -376
G-->A polymorphisms in Behcet’s disease. Clin Exp Rheumatol 2003;
21 (Suppl 30): 15-8.
25. Oz D, Karsli F, Atalay A, Sahin S. TNF-alpha gene polymorphisms
in Behcet’s disease. In: Bang D, Lee ES, Lee S, eds. Proceedings of
the 9th international conference on Behcet’s disease, Design Mecca
Publishing Seoul, 2000: 161-5.
26. Gul A. Behcet’s disease: an update on the pathogenesis. Clin Exp
Rheumatol 2001; 19 (Suppl 24): 6-12.
27. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G,
Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C,
Huhse B, Mangano R, Michon AM, Schirle M, Schlegl J, Schwab M,
Stein MA, Bauer A, Casari G, Drewes G, Gavin AC, Jackson DB,
Joberty G, Neubauer G, Rick J, Kuster B, Superti-Furga G. A physi-
cal and functional map of the human TNF-alpha/NF-kappa B signal
transduction pathway. Nat Cell Biol 2004; 6: 97-105.
28. Udalova IA, Richardson A, Denys A, Smith C, Ackerman H, Foxwell
B, Kwiatkowski D. Functional consequences of a polymorphism
affecting NF-kappaB p50-p50 binding to the TNF promoter region.
Mol Cell Biol 2000; 20: 9113-9.
29. van Heel DA, Udalova IA, De Silva AP, McGovern DP, Kinouchi
Y, Hull J, Lench NJ, Cardon LR, Carey AH, Jewell DP, Kwiatkows-
ki D. Inflammatory bowel disease is associated with a TNF polymor-
phism that affects an interaction between the OCT1 and NF (-kappa)
B transcription factors. Hum Mol Genet 2002; 11: 1281-9.
30. Verity DH, Wallace GR, Vaughan RW, Kondeatis E, Madanat W,
Zureikat H, Fayyad F, Marr JE, Kanawati CA, Stanford MR. HLA
and tumour necrosis factor (TNF) polymorphisms in ocular Behcet’s
disease. Tissue Antigens 1999; 54: 264-72.
31. Park KS, Min K, Nam JH, Bang D, Lee ES, Lee S. Association of
HYPA haplotype in the mannose-binding lectin gene-2 with Behcet’s
disease. Tissue Antigens 2005; 65: 260-5.
32. Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP,
Svejgaard A. Interplay between promoter and structural gene vari-
ants control basal serum level of mannan-binding protein. J Immunol
1995; 155: 3013-20.